Background: In utero opioid exposure can result in neonatal abstinence syndrome (NAS). NAS incidence has increased five-fold in the last decade. NAS is a serious condition characterized by central nervous system hyperirritability and autonomic nervous system and gastrointestinal tract dysfunction. Newborns with NAS may have several potential complications, may require pharmacological management, have increased hospital [...]

Background: Neonatal abstinence syndrome (NAS) occurs when an infant is exposed to licit or illicit chemical substances in utero and manifests symptoms of withdrawal from the substance(s) after birth. NAS is a clinical diagnosis, but is generally confirmed with testing of infant urine and/or meconium to identify specific causative substances. Appropriate identification, documentation, and communication [...]

Background: Neonatal abstinence syndrome (NAS) occurs when an infant is exposed to chemical substances in utero and consequently withdrawals from the substance(s) after birth. The long-term impact of NAS remains unclear due to confounding by other factors that impact infant health and development, but literature suggests that infants with NAS have motor and cognitive delays [...]

Background: Neonatal abstinence syndrome (NAS) occurs when a neonate is exposed to licit or illicit chemical substances in utero and manifests withdrawal symptoms postnatally. Appropriate identification, documentation, and communication of NAS diagnosis is needed to qualify for federally funded therapies aimed at supporting development through early intervention (EI) programs. Our objective was to assess characteristics [...]